sponsored content
Phase IIB Clinical Trial Shows EVNol SupraBio™ Benefits Diabetic Nephropathy
10 May 2021Oral supplementation of EVNol SupraBio™ for 12 months significantly improves renal function
Oral supplementation of EVNol SupraBio™ for 12 months significantly improves renal function in diabetic nephropathy subjects as assessed by serum creatinine [1].
In 2014, the
global prevalence of diabetes was reported by the World Health Organization
(WHO) to be 8.5% (422 million adults), which is almost double the figure as
compared to 4.7% (108 million adults) in 1980 [2]. Diabetic
nephropathy (also known as diabetic kidney disease) is one of the microvascular
complications of diabetes. This complication can lead to end-stage renal
failure (ESRF), hence it is crucial to halt this complication from getting
serious.
In a multicenter,
double-blind, randomized placebo-controlled Phase IIB study, 59 diabetic
nephropathy patients were randomized to receive either 200 mg EVNol SupraBio™
(encapsulated in softgel Tocovid Suprabio™) twice daily, or placebo. An
increase in estimated glomerular filtration rate (eGFR) and a decrease in serum
creatinine denote improvement in renal function. Patients with declined eGFR of
≥2 mL/min/1.73m2 per year will be identified as progressors and have
higher chances to eventually progress to ESRF.
EVNol
SupraBio™ supplementation significantly increased creatinine clearance and eGFR
at twelve months of supplementation. These changes were sustained throughout
the study period of a year. There was a reduction in serum creatinine levels of
7.85 umol/L in the EVNol SupraBio™ group with a corresponding 4.83 ml/min/1.73m2
increase of eGFR. On the other hand, subjects in the placebo group have a rate
of eGFR declined in approximation to 2.26ml/min/1.73m2 over a year.
After 6
months of cessation of EVNol SupraBio™, a significant reduction in urine to
albumin-creatinine ratio (UACR) by 19.3 mg/mmol was recorded. In contrast,
placebo group showed an increase in UACR by 4.6 mg/mmol. The urine
albumin-to-creatinine ratio (UACR) shows whether there is albumin in your
urine. People with a high amount of albumin in their urine are at an increased
risk of having chronic kidney disease progress to kidney failure.
As
per the researcher’s knowledge, this is the first clinical trial that
demonstrated tocotrienol-rich vitamin E supplementation for a short period of 12
months was able to ameliorate the progression of diabetic nephropathy
especially in patients with stage 3 chronic kidney disease.
References
1. Koay, Y. Y.,
Tan, G. C. J., Phang, S. C. W., Ho, J. I., Chuar, P. F., Ho, L. S., ... &
Abdul Kadir, K. (2021). A Phase IIb Randomized Controlled Trial Investigating
the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease. Nutrients, 13(1), 258.
2. Global
report on diabetes: World Health Organization; 2016.